# Colin Broom

> Colin Broom is a physician, pharmaceutical-medicine specialist and biotechnology executive who has worked across the full arc of drug development. After senior roles at Glaxo, SmithKline Beecham, Hoechst Marion Roussel and Amgen, he became chief scientific officer at ViroPharma, led Nabriva Therapeutics through a $106.1 million public offering, and joined Pulmotect as CEO in 2019. His current assignment is advancing the Houston company's inhaled candidate PUL-042, including a 100-patient Phase 2 trial that began dosing in 2025.

- **Role:** Chief Executive Officer at Pulmotect, Inc.
- **Organizations:** Pulmotect, Inc., Nabriva Therapeutics, ViroPharma, Amgen, Hoechst Marion Roussel, SmithKline Beecham, Glaxo, NPS Pharmaceuticals, Royal College of Physicians, Faculty of Pharmaceutical Medicine
- **Education:** BSc in Pharmacology, University College London, Bachelor of Medicine and Bachelor of Surgery; clinical training, St George's Hospital Medical School, London
- **Known for:** Led Nabriva Therapeutics through a $106.1 million initial public offering in 2015., Helped develop lefamulin during his tenure at Nabriva; the drug was approved by the FDA in 2019., Led research and development and medical affairs at ViroPharma before its acquisition by Shire.

## Career timeline

- **Before 2000** — Held roles of increasing seniority at Glaxo and SmithKline Beecham, including leadership of oncology and later CNS and gastrointestinal development areas.
- **Before 2000** — Served as senior vice president of global clinical development at Hoechst Marion Roussel, with responsibility for clinical development strategy across therapeutic areas.
- **2000-2003** — Led European clinical development and medical affairs at Amgen.
- **2004** — Joined ViroPharma as vice president and chief scientific officer, responsible for product development and strategic business development.
- **2009-2015** — Served on the board of NPS Pharmaceuticals until its acquisition by Shire.
- **2014** — Left ViroPharma after its acquisition by Shire and became CEO of Nabriva Therapeutics.
- **2015** — Led Nabriva through a $106.1 million initial public offering.
- **2018** — Stepped down as Nabriva CEO, remaining on its board through 2023.
- **2019** — Joined Pulmotect as chief executive officer.
- **2024** — Pulmotect closed an oversubscribed $5.9 million Series C led by Fannin Partners with participation from Axil Capital.
- **2025** — Pulmotect began dosing a 100-patient, double-blind, placebo-controlled Phase 2 trial of PUL-042.

## Achievements

- Led Nabriva Therapeutics through a $106.1 million initial public offering in 2015.
- Helped develop lefamulin during his tenure at Nabriva; the drug was approved by the FDA in 2019.
- Led research and development and medical affairs at ViroPharma before its acquisition by Shire.
- Made major contributions to development, regulatory approval or commercialization programs across multiple therapeutic areas, including programs for Lantus, Hycamtin, Paxil, Requip, Kytril and Famvir.
- Is a member of the Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine.
- Is named as an inventor on multiple pharmaceutical patent filings and grants.

## Latest updates

- **2025-07** — Pulmotect announced that dosing had begun in its 100-patient Phase 2 trial of PUL-042.
- **2025-05** — Pulmotect listed a new peer-reviewed paper on immune modulation with nebulized pattern-recognition receptor agonists among its published research.
- **2024-09** — Pulmotect announced an oversubscribed $5.9 million Series C led by Fannin Partners with participation from Axil Capital.

## Links

- Website: https://pulmotect.com
- LinkedIn: https://www.linkedin.com/in/colin-broom-51b56915
- Twitter/X: https://twitter.com/pulmotect

---

Profile page: https://yespress.io/colin-broom
Published by YesPress — https://yespress.io
Last updated: 2026-09-27